The extent to which targeting non-apoptotic death pathways in p53-deficient cancers would improve therapeutic responses remains to be determined, but our studies reveal the prominent use of MPT-driven necrosis in p53-deficient cancers, and the genetic determinants for DNA damage-induced and MPT-driven cell death. The gene discussed is TP53; the disease is cancer.